Biological Highlights of ASH 2024

Expert:
Professor Susan Branford
Head, Leukemia Unit, Genetics and Molecular Pathology, SA Pathology, Adelaide (Australia)

Program:
Overview of significant biological aspects presented during the meeting, including:

BCR::ABL1 protein degraders
Abstract 4157: Targeting CML with potent and specific BCR::ABL1 degraders (Cruz-Rodriguez N et al.)
Abstract 1387: An orally active pan-BCR::ABL1 degrader Tgrx-3247 potentially targets a wide spectrum of orthosteric, allosteric and compound mutations resistant to TKI therapies (Wang Y et al.)

Novel biomarkers of treatment-free remission
Abstract 993: Increased inflammatory cytokines in plasma are associated with sustained treatment-free remission (Ross D et al.) 

Blood cancer-related gene variants at diagnosis and treatment outcome
Abstract 991: Strong association between cancer gene variants at diagnosis, especially ASXL1, and emergence of kinase domain mutation-driven resistance in CML patients despite frontline treatment with more potent BCR::ABL inhibitors (Shanmunagathan N et al.)
Abstract 1774: The combination of asciminib with ATP competing TKIs might overcome the negative impact of ASXL1 mutations on molecular response in newly diagnosed CML patients (Ernst T et al.)

Questions and Answers (Clinical and biological)

To see Professor Timothy Hughes' overview of the clinical hilights, go here:    • Clinical Highlights of ASH 2024  

00:00 Introduction
01:23 BCR::ABL1 protein degraders
06:41 Novel biomarkers of treatment-free remission
09:23 Blood cancer-related gene variants at diagnosis and treatment outcome
18:00 Questions and Answers (Clinical and biological)